PDF herunterladen
Dtsch Med Wochenschr 2012; 137(48): 2498
DOI: 10.1055/s-0032-1327303
Pro & Contra | Commentary
Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Duale RAS-Blockade in der antihypertensiven Therapie – pro

Dual blockade of the renin-angiotensin system in hypertensive treatment: yes
M. Middeke
1   Hypertoniezentrum München
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
20. November 2012 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Schlüsselwörter

arterielle Hypertonie - Renin-Angiotensin-System - ONTARGET - ALTITUDE

Keywords

arterial hypertension - renin-angiotensin systeme - ONTARGET - ALTITUDE

Folgender Teil dieser Serie:

der Weg ist das Ziel!Dtsch Med Wochenschr 2012; 137(48): 2461-2461
DOI: 10.1055/s-0032-1330141

 

  • Literatur

  • 1 ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362 (17) 1575-1585
    CrossrefPubMedGoogle Scholar
  • 2 Haller H, Ito S, Izzo Jr JL et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
    CrossrefPubMedGoogle Scholar
  • 3 Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population. BMJ 2010; 340: b5465
    CrossrefPubMedGoogle Scholar
  • 4 Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study). Lancet 2008; 372: 547-553
    CrossrefPubMedGoogle Scholar
  • 5 Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; DOI: 10.1056/NEJMoa1208799.
    PubMedGoogle Scholar
  • 6 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
    CrossrefPubMedGoogle Scholar